Long-term Use of Cholesterol-Lowering Drugs and Cancer Incidence in a Large United States Cohort
Long-term Use of Cholesterol-Lowering Drugs and Cancer Incidence in a Large United States Cohort
复制标题
DOI：
10.1158/0008-5472.can-10-2953
复制
发表时间：
2011-03-01
期刊：
影响因子：
11.2
通讯作者：
Gapstur, Susan M.
中科院分区：
文献类型：
--
作者：
Jacobs, Eric J.;Newton, Christina C.;Gapstur, Susan M.
HMG-CoA还原酶抑制剂，通常称为他汀类药物，占降胆固醇药物使用的绝大多数。然而，关于长期使用他汀类药物与大多数类型癌症发病率之间的关系知之甚少。我们研究了1997年至2007年期间癌症预防研究II营养队列中133，255名参与者（60，059名男性和73，196名女性）长期使用降胆固醇药物（主要是他汀类药物）与10种常见癌症发病率以及总体癌症发病率之间的关系。多因素考克斯比例风险回归用于估计相对危险度（RR）。在随访期间，使用来自两年期随访问卷的信息更新当前使用状态和使用持续时间。目前使用降胆固醇药物5年或5年以上与总体癌症发病率无关（RR 0.97，95% CI = 0.92-1.03），或前列腺癌、乳腺癌、结直肠癌、肺癌、膀胱癌、肾细胞癌或胰腺癌的发病率，但与黑色素瘤风险降低相关（RR = 0.79，95%CI = 0.66-0.96）、子宫内膜癌（RR = 0.65，95%CI = 0.45-0.94）和非霍奇金淋巴瘤（NHL; RR = 0.74，95%CI = 0.62-0.89）。这些结果表明，长期使用他汀类药物不太可能大幅增加或降低总体癌症风险。然而，长期使用他汀类药物与子宫内膜癌、黑色素瘤和NHL风险之间的关系值得进一步研究。Cancer Res; 71（5）; 1763-71. (c)2011年AACR。
HMG-coA reductase inhibitors, commonly known as statins, account for the great majority of cholesterol-lowering drug use. However, little is known about the association between long-term statin use and incidence of most types of cancers. We examined the association between long-term use of cholesterol-lowering drugs, predominantly statins, and the incidence of ten common cancers, as well as overall cancer incidence, among 133,255 participants (60,059 men and 73,196 women) in the Cancer Prevention Study II Nutrition Cohort during the period from 1997 to 2007. Multivariate Cox proportional hazards regression was used to estimate relative risks (RR). Current use status and duration of use were updated during follow-up using information from biennial follow-up questionnaires. Current use of cholesterol-lowering drugs for five or more years was not associated with overall cancer incidence (RR 0.97, 95% CI = 0.92-1.03), or incidence of prostate, breast, colorectal, lung, bladder, renal cell, or pancreatic cancer but was associated with lower risk of melanoma (RR = 0.79, 95% CI = 0.66-0.96), endometrial cancer (RR = 0.65, 95% CI = 0.45-0.94), and non-Hodgkin lymphoma (NHL; RR = 0.74, 95% CI = 0.62-0.89). These results suggest that long-term use of statins is unlikely to substantially increase or decrease overall cancer risk. However, associations between long- term statin use and risk of endometrial cancer, melanoma, and NHL deserve further investigation. Cancer Res; 71(5); 1763-71. (c) 2011 AACR.